AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

By /

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17%.

Scroll to Top